Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
… (29.4%) patients. Glucocorticoids were received by 41 (80.4%), hydroxychloroquine - 38 (74.5%), immunosuppressants – 18 (35.3%) patients. Over th…
… a saline suppression test in 2025 confirmed PA. Treatment with spironolactone (25mg daily, later increased to 37.5mg) is ongoing, with partia…
…essants: calcineurin inhibitors (3/5), mycophenolate (2/5), and belimumab (1/5). The most frequent extrarenal manifestations were arthrit…
… class IV. She was treated with pulse IV Solumedrol followed by prednisone taper, HCQ, MMF and later one, MMF was switched to azathioprine…
… disease and gastrointestinal involvement. She was treated with mycophenolate mofetil for skin and lung disease, prednisolone for myositis, and maint…
…Objectives Systemic lupus erythematosus (SLE) is characterized by B cell-driven autoimmunity and an upr…
…Objectives Systemic Lupus Erythematosus (SLE) primarily affects females of reproductive age. Despite im…
…r disease (CVD). Literature on the matter is scarce and because Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) mainly affect women o…
…amide (CYC) are recommended therapies for inducing treatment in Lupus Nephritis (LN), with evidence showing similar effectiveness in improving …
…b in 25, belimumab in 16, obinutuzumab in 2, voclosporin in 21, tacrolimus in 6, cyclosporin-A in 4 and azathioprine in 3 patients. Six pa…
… allowing patients to achieve meaningful clinical responses off SLE therapies. Both cohorts are fully enrolled, with additional pos…
…Objectives Anifrolumab is a biologic recently approved for systemic lupus erythematosu…